The Form 4 filing for CYTK was submitted on October 13, 2026. This report of changes in insider share ownership lists October 12, 2026, as the sale date.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-12 |
| Date of Latest Transaction | 2026-10-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 7,500 |
| Price | $62.88 |
| Total Transaction Value | $471,600.00 |
| Insider | |
| Ticker Symbol | CYTK |
| Company | CYTOKINETICS INC |
| Insider Name | Blum Robert I |
| Insider Title | President & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 278,544 |
| Position Size Change | 2.62% |
| Filing | |
| Filing Date | 2026-10-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S. The details also suggest a link to an exercise or conversion. These steps can turn an existing right or another holding into shares.
What was the average price of the transaction?
The average sale price was $62.88 per share.
How did this transaction affect the insider's holdings?
Robert I. Blum sold 7,500 shares and reported owning 278,544 shares afterward. The sale represented 2.62% of his reported shares owned before the sale.
What's the total transaction value?
The total reported sale value was $471,600.00, covering one transaction.
Are there any special circumstances around this transaction?
The available information points to a Rule 10b5-1 plan, which sets trading instructions in advance. It does not confirm whether that plan covered this specific sale, when it began, or its terms.
Matching share counts also suggest a link between the sale and an exercise or conversion in the same filing. Details of the related shares received and the filing's footnotes are unavailable. The match alone does not confirm matching dates, types of shares, or accounts. It also does not establish that the shares received were the ones sold, or explain why the sale occurred.
For research purposes only; not investment advice.